Onco-Summaries: Daily Oncology Updates at a Glance

20/03/2026

---

• BMS received approvals from US FDA and EC for Opdivo-based treatment combinations for classical Hodgkin Lymphoma

---

BMS received approvals from US FDA and EC for Opdivo-based treatment combinations for classical Hodgkin Lymphoma (Ref)

The US FDA approved Bristol Myers Squibb's nivolumab (anti-PD-1) + doxorubicin + vinblastine + dacarbazine for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL. Additionally, the EC approved nivolumab + brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy.

• The US approval is based on the Phase 3 SWOG 1826 (CA2098UT) trial. A submission based on SWOG 1826 is also currently under evaluation by the EMA

• The EU approval is based on the Phase 2 CheckMate-744 trial

Return to Top